Anti-Human LAG-3 Recombinant Nanobody (SAA2195) (HB613013)

Name: Anti-Human LAG-3 Recombinant Nanobody (SAA2195)
Brand: abinScience
SKU: HB613013
Price: 126 USD
Availability: InStock

Datasheet Compartir producto Copiar información

Precio(USD):

Especificación:

20ug
50ug
100ug
1mg

Número:

Contáctenos

Vista general
Imágenes
Referencias
Datasheet
SDS

Vista general

Número de catálogo

HB613013

Descripción

Anti-Human LAG3 Nanobody (SAA2195) [SAA2195] (HB613013) is a alpaca monoclonal antibody detecting LAG3 in ELISA. Suitable for Human.

Reactividad de especies

Human

Aplicaciones

ELISA

Especie huésped

Alpaca

Clonalidad

Monoclonal

Isotipo

VHH-8His-Cys-tag

ID de clon

SAA2195

Objetivo

CD223, FDC, LAG-3, LAG3, Lymphocyte activation gene 3 protein, Secreted lymphocyte activation gene 3 protein, sLAG-3

Nivel de endotoxinas

< 10 EU/mg

Pureza

>95% as determined by SDS-PAGE.

Purificación

Protein A/G purified from cell culture supernatant.

Número de acceso

P18627

Forma

Liquid

Buffer de almacenamiento

0.01M PBS pH 7.4.

Consulte la información específica del buffer en la copia impresa del datasheet o en el COA específico del lote.

Información de uso del producto

Aplicación	Dilución
ELISA	1:2000-1:20000

Estabilidad y almacenamiento

Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.

Fondo

Lymphocyte activation gene 3 protein (CD223/LAG3) is a ~57 kDa protein. Inhibitory receptor on antigen activated T-cells. Delivers inhibitory signals upon binding to ligands, such as MHC class II, its main ligand present at the surface of antigen-presenting cells (APCs), and FGL1, which is secreted by hepatocytes and certain types of tumor cells. Ligand-binding initiates a signaling that inhibits the T-cell receptor (TCR) in the immunological synapse, preventing T-cell activation. Mechanistically, ligand-binding promotes (1) ubiquitination of the KIEELE motif, unleashing the RRFSALE motif from the membrane and (2) leading to the formation of condensates with the TCR component CD3E, thereby disrupting the association between CD3E and LCK and preventing TCR activation. May inhibit antigen-specific T-cell activation in synergy with PDCD1/PD-1. CD223 is the therapeutic target of relatlimab (Opdualag).

1. Camisaschi, C. et al. (2010) Journal of immunology (Baltimore, Md. : 1950) 184, 6545-51. PMID: 20421648

2. Ming, Q. et al. (2022) Nature immunology 23, 1031-1041. PMID: 35761082

3. Huard, B. et al. (1994) European journal of immunology 24, 3216-21. PMID: 7805750

4. Huard, B. et al. (1996) European journal of immunology 26, 1180-6. PMID: 8647185

5. Wang, J. et al. (2019) Cell 176, 334-347.e12. PMID: 30580966

6. MacLachlan, BJ. et al. (2021) European journal of immunology 51, 331-341. PMID: 32920841

7. Petersen, J. et al. (2024) Science immunology 9, eads5122. PMID: 39671469

8. Huard, B. et al. (1995) European journal of immunology 25, 2718-21. PMID: 7589152

10. Jiang, Y. et al. (2025) Cell 188, 2354-2371.e18. PMID: 40101708

Nota

For research use only.

Imágenes

SDS-PAGE

SDS-PAGE for Anti-Human LAG3 Nanobody (SAA2195)

Referencias

Datasheet

Anti-Human LAG-3 Recombinant Nanobody (SAA2195).pdf

Download SDS PDF

Formula

Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)

Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.

Mass

Concentration

Volume

Molecular Weight *

g/mol

Formula

C₁ × V₁ = C₂ × V₂

Enter any 3 of the 4 values to solve for the unknown.

Stock Solution

C₁ (Stock Conc.)

V₁ (Stock Vol.)

Working Solution

C₂ (Working Conc.)

V₂ (Working Vol.)

Proteínas Recombinantes

Anticuerpos

Kits de Ensayo